Cisatracurium besylate injection has a market value of approximately $14 million in the 12 months ending January 2025, per ...

Hikma Pharmaceuticals PLC HIK shares slipped 1.68% to £19.86 Monday, on what proved to be an all-around rough trading session ...

Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, announces the approval of KLOXXADO ® (naloxone HCl) Nasal Spray 8 mg, by Health Canada for the treatment of ...

Hikma Pharmaceuticals (HKMPF) announces the approval of KLOXXADO Nasal Spray 8 mg, by Health Canada for the treatment of known or suspected ...

Hikma Pharmaceuticals PLC closed 11.86% below its 52-week high of £23.60, which the company reached on February 13th.

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are ...

Blog posts represent the views of CFR fellows and staff and not those of CFR, which takes no institutional positions. Most of the major U.S. pharmaceutical companies (AbbVie, Amgen, Bristol Myers ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Collegium Pharmaceutical Inc. is a specialty pharma ... The company has secured a generic agreement with Hikma for production of the drug post-exclusivity period. Sales in 2024 were $100.7 million ...